Transplantation Reviews最新文献

{"title":"Non-tuberculous mycobacteria disease pre-lung transplantation: A systematic review of the treatment regimens and duration pre- and post-transplant.","authors":"Johanna P. van Gemert ,&nbsp;Sofanne J. Ravensbergen ,&nbsp;Erik A.M. Verschuuren ,&nbsp;Huib A.M. Kerstjens ,&nbsp;Brigitte W.M. Willemse ,&nbsp;Jakko van Ingen ,&nbsp;Wouter Hoefsloot ,&nbsp;Tji Gan ,&nbsp;Onno W. Akkerman","doi":"10.1016/j.trre.2023.100800","DOIUrl":"10.1016/j.trre.2023.100800","url":null,"abstract":"<div><h3>Background</h3><p>There is lack of consensus on non-tuberculous mycobacteria pulmonary disease (NTM-PD) treatment regimen and duration in patient listed for lung transplantation (LTx). We conducted a systematic review on treatment regimen and duration pre- and directly post-LTx, for patients with known NTM-PD pre-LTx. Additionally, we searched for risk factors for NTM disease development post-LTx and for mortality.</p></div><div><h3>Methods</h3><p>Literature was reviewed on PubMed, Embase and the Cochrane Library, for articles published from inception to January 2022. Individual patient data were sought.</p></div><div><h3>Results</h3><p>Sixteen studies were included reporting 92 patients. Most frequent used agents were aminoglycosides and macrolides for <em>Mycobacterium abscessus</em> (<em>M. abscessus</em>) and macrolides and tuberculostatic agents for <em>Mycobacterium avium</em> complex (<em>M. avium</em> complex). The median treatment duration pre-LTx was 10 months (IQR 6–17) and 2 months (IQR 2–8) directly post-LTx. Longer treatment duration pre-LTx was observed in children and in patients with <em>M. abscessus</em>. 46% of the patients with NTM-PD pre-LTx developed NTM disease post-LTx, related mortality rate was 10%. Longer treatment duration pre-LTx (<em>p</em> &lt; 0.001) and sputum non-conversion pre-LTx (<em>p</em> = 0.003) were significantly associated with development of NTM-disease post-LTx. Longer treatment duration pre-LTx (<em>p</em> = 0.004), younger age (<em>p</em> &lt; 0.001) and sputum non-conversion (<em>p</em> = 0.044) were risk factors for NTM related death.</p></div><div><h3>Conclusions</h3><p>The median treatment duration pre-LTx was 10 months (IQR 6–17) and 2 months (IQR 2–8) directly post-LTx. Patients with longer treatment duration for NTM-PD pre-LTx and with sputum non-conversion are at risk for NTM disease post-LTx and for NTM-related death. Children were particularly at risk for NTM related death.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100800"},"PeriodicalIF":4.0,"publicationDate":"2023-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of an aneurysmal arteriovenous fistula in kidney transplant recipients","authors":"Michael Corr ,&nbsp;Kateřina Lawrie ,&nbsp;Peter Baláž ,&nbsp;Stephen O'Neill","doi":"10.1016/j.trre.2023.100799","DOIUrl":"10.1016/j.trre.2023.100799","url":null,"abstract":"<div><p>Aneurysms remain the most common complication of an arteriovenous fistula created for dialysis access. The management of an aneurysmal arteriovenous fistula (AAVF) in kidney transplant recipients remains contentious with a lack of clear clinical guidelines. Recipients of a functioning graft do not require the fistula for dialysis access, however risk of graft failure and needing the access at a future date must be considered. In this review we outline the current evidence in the assessment and management of a transplant recipient with an AAVF. We will describe our recommended five-step approach to assessing an AAVF in transplant patients; 1.) Define AAVF 2.) Risk assess AAVF 3.) Assess transplant graft function and future graft failure risk 4.) Consider future renal replacement therapy options 5.) Vascular mapping to assess future vascular access options. Then we will describe the current therapeutic options and when they would most appropriately be employed.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100799"},"PeriodicalIF":4.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What are the benefits of preemptive versus non-preemptive kidney transplantation? A systematic review and meta-analysis","authors":"Reshma Rana Magar ,&nbsp;Simon R. Knight ,&nbsp;Umberto Maggiore ,&nbsp;Jeffrey A. Lafranca ,&nbsp;Frank J.M.F. Dor ,&nbsp;Liset H.M. Pengel","doi":"10.1016/j.trre.2023.100798","DOIUrl":"10.1016/j.trre.2023.100798","url":null,"abstract":"<div><p>Opting for a preemptive kidney transplant (PKT) can help avoid costs and morbidity associated with dialysis. However, while multiple studies have shown clinical benefits of PKT, other studies have not demonstrated this, leading to controversy in the literature regarding the exact benefits of PKT. Therefore, this study aimed to determine the clinical outcomes of PKT versus non-preemptive kidney transplantation (nPKT) in adult patients. Multiple databases were searched up to May 4, 2022. Independent reviewers selected studies for inclusion and extracted relevant data. Risk of bias was assessed using the Downs and Black checklist. Eighty-seven studies including 859,715 adult kidney transplant patients were included the review. The risk of patient death (relative risk [95% confidence interval] 0.74 [0.60–0.91]) was significantly lower in PKT versus nPKT patients for living donor (LD) transplants, whereas the risk of overall graft loss was significantly lower in PKT compared to nPKT patients for both LD (0.72 [0.62–0.83]) as well as deceased donor (DD) transplants (0.80 [0.69–0.92]). The evidence suggests that LD PKT patients have a lower risk of patient death and graft loss compared to nPKT patients, and DD PKT patients have a lower risk of graft loss than nPKT patients.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100798"},"PeriodicalIF":4.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41167141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative fibrinogen level and blood transfusions in liver transplantation: A systematic review","authors":"Félix Thibeault ,&nbsp;Guillaume Plourde ,&nbsp;Massine Fellouah ,&nbsp;Daniela Ziegler ,&nbsp;François Martin Carrier","doi":"10.1016/j.trre.2023.100797","DOIUrl":"10.1016/j.trre.2023.100797","url":null,"abstract":"<div><h3>Background</h3><p><span>Orthotopic liver transplantation (OLT) is a major surgery often associated with significant bleeding. We conducted a </span>systematic review<span><span> to explore the association between preoperative fibrinogen level and intraoperative blood products transfusion, blood loss and clinical outcomes </span>in patients undergoing OLT.</span></p></div><div><h3>Methods</h3><p>We included observational studies conducted in patients undergoing an OLT mostly for end-stage liver disease that reported an association between the preoperative fibrinogen level and our outcomes of interest. Our primary outcome was the intraoperative red blood cell (RBC) transfusion requirements. Our secondary outcomes were intraoperative blood loss, intraoperative transfusion of any blood product, postoperative RBC transfusion, postoperative thrombotic or hemorrhagic complications, and mortality. We used a standardized search strategy. We reported our results mostly descriptively but conducted meta-analyses using random-effect models when judged feasible.</p></div><div><h3>Results</h3><p><span>We selected 24 cohort studies reporting at least one of our outcomes. We found that a high preoperative fibrinogen level was associated with fewer intraoperative RBC and other blood products transfusions, and lower blood loss. We also found a lower overall survival in patients with a higher fibrinogen level (pooled hazard ratio [95% CI] of 1.50 [1.23 to 1.84]; 5 studies, </span><em>n</em> = 1012, I² = 48%). Only one study formally explored a fibrinogen level threshold effect. Overall, reporting was heterogeneous, and risk of bias was variable mostly because of uncontrolled confounding.</p></div><div><h3>Conclusion</h3><p>A higher preoperative fibrinogen level was associated with fewer intraoperative RBC and other blood products transfusions, lower blood loss, and higher mortality. Further studies may help clarify observed associations and inform guidelines.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100797"},"PeriodicalIF":4.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis","authors":"Nuria Montero ,&nbsp;Emilio Rodrigo ,&nbsp;Marta Crespo ,&nbsp;Josep M. Cruzado ,&nbsp;Alex Gutierrez-Dalmau ,&nbsp;Auxiliadora Mazuecos ,&nbsp;Asunción Sancho ,&nbsp;Lara Belmar ,&nbsp;Emma Calatayud ,&nbsp;Paula Mora ,&nbsp;Laia Oliveras ,&nbsp;Eulalia Solà ,&nbsp;Florentino Villanego ,&nbsp;Julio Pascual","doi":"10.1016/j.trre.2023.100795","DOIUrl":"10.1016/j.trre.2023.100795","url":null,"abstract":"<div><h3>Background</h3><p>Recommendations of the use of antibody induction treatments in kidney transplant recipients (KTR) are based on moderate quality and historical studies. This systematic review aims to reevaluate, based on actual studies, the effects of different antibody preparations when used in specific KTR subgroups.</p></div><div><h3>Methods</h3><p>We searched MEDLINE and CENTRAL and selected randomized controlled trials (RCT) and observational studies looking at different antibody preparations used as induction in KTR. Comparisons were categorized into different KTR subgroups: standard, high risk of rejection, high risk of delayed graft function (DGF), living donor, and elderly KTR. Two authors independently assessed the risk of bias.</p></div><div><h3>Results</h3><p>Thirty-seven RCT and 99 observational studies were finally included. Compared to anti-interleukin-2-receptor antibodies (IL2RA), anti-thymocyte globulin (ATG) reduced the risk of acute rejection at two years in standard KTR (RR 0.74, 95%CI 0.61–0.89) and high risk of rejection KTR (RR 0.55, 95%CI 0.43–0.72), but without decreasing the risk of graft loss. We did not find significant differences comparing ATG vs. alemtuzumab or different ATG dosages in any KTR group.</p></div><div><h3>Conclusions</h3><p>Despite many studies carried out on induction treatment in KTR, their heterogeneity and short follow-up preclude definitive conclusions to determine the optimal induction therapy. Compared with IL2RA, ATG reduced rejection in standard-risk, highly sensitized, and living donor graft recipients, but not in high DGF risk or elderly recipients. More studies are needed to demonstrate beneficial effects in other KTR subgroups and overall patient and graft survival.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100795"},"PeriodicalIF":4.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The British Transplantation Society guidelines on cardiothoracic organ transplantation from deceased donors after circulatory death","authors":"Vasudev Pai ,&nbsp;Ellie Asgari ,&nbsp;Marius Berman ,&nbsp;Chris Callaghan ,&nbsp;Paul Corris ,&nbsp;Stephen Large ,&nbsp;Simon Messer ,&nbsp;David Nasralla ,&nbsp;Jas Parmar ,&nbsp;Chris Watson ,&nbsp;Stephen O'Neill","doi":"10.1016/j.trre.2023.100794","DOIUrl":"10.1016/j.trre.2023.100794","url":null,"abstract":"<div><p>Maximising organ utilisation from donation after circulatory death (DCD) donors could help meet some of the shortfall in organ supply, but it represents a major challenge, particularly as organ donors and transplant recipients become older and more medically complex over time. Success is dependent upon establishing common practices and accepted protocols that allow the safe sharing of DCD organs and maximise the use of the DCD donor pool. The British Transplantation Society ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated. This manuscript summarises the relevant recommendations from chapters specifically related to transplantation of cardiothoracic organs.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100794"},"PeriodicalIF":4.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10201580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of denosumab on bone metabolism and bone mineral density in renal transplant recipients: A systematic review and meta-analysis","authors":"Peiqin Zhu ,&nbsp;Tong Yang ,&nbsp;Jun Le ,&nbsp;Xiaoting Fu ,&nbsp;Liang Zhang","doi":"10.1016/j.trre.2023.100793","DOIUrl":"10.1016/j.trre.2023.100793","url":null,"abstract":"<div><h3>Background</h3><p><span>Post-transplant bone disease (PTBD) is a common complication in kidney transplant recipients. This </span>systematic review<span> and meta-analysis evaluates the efficiency and safety of denosumab<span> for the treatment of PTBD in kidney transplant recipients.</span></span></p></div><div><h3>Methods</h3><p>Comprehensive search of PubMed Central, SCOPUS, EMBASE, MEDLINE, Cochrane trial registry, Google Scholar, and <span>Clinicaltrials.gov</span><svg><path></path></svg><span> databases was done for studies, published until April 2023. Primary outcomes included changes in bone mineral density (BMD) and T-scores. Secondary outcomes included incidence of fractures, alterations in bone turnover markers, and the incidence of adverse events.</span></p></div><div><h3>Results</h3><p>Eleven studies with a total of 511 participants that underwent kidney transplant were included. Denosumab treatment resulted in a significant improvement in lumbar spine<span> BMD (SMD: -0.31, 95% CI: −0.56 to −0.06) and T-score (SMD: -1.07, 95% CI: −1.51 to −0.64), while no differences were detected in hip/femoral neck BMD and the T-score. There was no marked change in the fracture incidence (OR: 0.42, 95% CI: 0.06 to 3.07). However, patients who received denosumab treatment had an increased incidence rate of hypocalcemia (OR: 9.98, 95% CI: 1.72 to 57.88).</span></p></div><div><h3>Conclusions</h3><p><span>Denosumab treatment may improve lumbar spine BMD and T-scores in patients with PTBD. However, it does not significantly affect fracture incidence and may increase the risk of hypocalcemia. These findings underline the necessity for well-powered, </span>randomized controlled trials to further clarify the role of denosumab in managing PTBD.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100793"},"PeriodicalIF":4.0,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10139977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review","authors":"Chandrashekar Annamalai ,&nbsp;Vivek Kute ,&nbsp;Carl Sheridan ,&nbsp;Ahmed Halawa","doi":"10.1016/j.trre.2023.100792","DOIUrl":"10.1016/j.trre.2023.100792","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;p&gt;Despite its use to prevent acute rejection, lifelong immunosuppression can adversely impact long-term patient and graft outcomes. In theory, immunosuppression withdrawal is the ultimate goal of kidney transplantation, and is made possible by the induction of immunological tolerance. The purpose of this paper is to review the safety and efficacy of immune tolerance induction strategies in living-donor kidney transplantation, both chimerism-based and non-chimerism-based. The impact of these strategies on transplant outcomes, including acute rejection, allograft function and survival, cost, and immune monitoring, will also be discussed.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;p&gt;Databases such as PubMed, Scopus, and Web of Science, as well as additional online resources such as EBSCO, were exhaustively searched. Adult living-donor kidney transplant recipients who developed chimerism-based tolerance after concurrent bone marrow or hematopoietic stem cell transplantation or those who received non-chimerism-based, non-hematopoietic cell therapy using mesenchymal stromal cells, dendritic cells, or regulatory T cells were studied between 2000 and 2021. Individual sources of evidence were evaluated critically, and the strength of evidence and risk of bias for each outcome of the transplant tolerance study were assessed.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;From 28,173 citations, 245 studies were retrieved after suitable exclusion and duplicate removal. Of these, 22 studies (2 RCTs, 11 cohort studies, 6 case-control studies, and 3 case reports) explicitly related to both interventions (chimerism- and non-chimerism-based immune tolerance) were used in the final review process and were critically appraised. According to the findings, chimerism-based strategies fostered immunotolerance, allowing for the safe withdrawal of immunosuppressive medications. Cell-based therapy, on the other hand, frequently did not induce tolerance except for minimising immunosuppression. As a result, the rejection rates, renal allograft function, and survival rates could not be directly compared between these two groups. While chimerism-based tolerance protocols posed safety concerns due to myelosuppression, including infections and graft-versus-host disease, cell-based strategies lacked these adverse effects and were largely safe.&lt;/p&gt;&lt;p&gt;There was a lack of direct comparisons between HLA-identical and HLA-disparate recipients, and the cost implications were not examined in several of the retrieved studies. Most studies reported successful immunosuppressive weaning lasting at least 3 years (ranging up to 11.4 years in some studies), particularly with chimerism-based therapy, while only a few investigators used immune surveillance techniques. The studies reviewed were often limited by selection, classification, ascertainment, performance, and attrition bias.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;This review demonstrates that chimerism-based hematopoietic ","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100792"},"PeriodicalIF":4.0,"publicationDate":"2023-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally and Non-invasive Approaches to Rejection Identification in Vascularized Composite Allotransplantation","authors":"Thor S. Stead ,&nbsp;Hilliard T. Brydges ,&nbsp;Matteo Laspro ,&nbsp;Ogechukwu C. Onuh ,&nbsp;Bachar F. Chaya ,&nbsp;Piul S. Rabbani ,&nbsp;Catherine P. Lu ,&nbsp;Daniel J. Ceradini ,&nbsp;Bruce E. Gelb ,&nbsp;Eduardo D. Rodriguez","doi":"10.1016/j.trre.2023.100790","DOIUrl":"10.1016/j.trre.2023.100790","url":null,"abstract":"<div><h3>Objective</h3><p><span>Rejection is common and pernicious following Vascularized Composite Allotransplantation (VCA). Current monitoring and diagnostic modalities include the clinical exam which is subjective and biopsy with dermatohistopathologic Banff grading, which is subjective and invasive. We reviewed literature exploring non- and minimally invasive modalities for diagnosing and monitoring rejection (NIMMs) in </span>VCA.</p></div><div><h3>Methods</h3><p>PubMed, Cochrane, and Embase databases were queried, 3125 unique articles were reviewed, yielding 26 included studies exploring 17 distinct NIMMs. Broadly, NIMMs involved Imaging, Liquid Biomarkers, Epidermal Sampling, Clinical Grading Scales, and Introduction of Additional Donor Tissue.</p></div><div><h3>Results</h3><p>Serum biomarkers including MMP3<span> and donor-derived microparticles<span> rose with rejection onset. Epidermal sampling non-invasively enabled measurement of cytokine &amp; gene expression profiles implicated in rejection. Both hold promise for monitoring. Clinical grading scales were useful diagnostically as was reflection confocal microscopy. Introducing additional donor tissue showed promise for preemptively identifying rejection but requires additional allograft tissue burden for the recipient.</span></span></p></div><div><h3>Conclusion</h3><p>NIMMs have the potential to dramatically improve monitoring and diagnosis in VCA. Many modalities show promise however, additional research is needed and a multimodal algorithmic approach should be explored.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100790"},"PeriodicalIF":4.0,"publicationDate":"2023-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10070290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The British transplantation society guidelines on organ donation from deceased donors after circulatory death","authors":"Stephen O'Neill ,&nbsp;Ellie Asgari ,&nbsp;Chris Callaghan ,&nbsp;Dale Gardiner ,&nbsp;Hermien Hartog ,&nbsp;Satheesh Iype ,&nbsp;Alex Manara ,&nbsp;David Nasralla ,&nbsp;Gabi C. Oniscu ,&nbsp;Chris Watson","doi":"10.1016/j.trre.2023.100791","DOIUrl":"10.1016/j.trre.2023.100791","url":null,"abstract":"<div><p>Recipient outcomes after transplantation with organs from donation after circulatory death (DCD) donors can compare favourably and even match recipient outcomes after transplantation with organs from donation after brain death donors. Success is dependent upon establishing common practices and accepted protocols that allow the safe sharing of DCD organs and maximise the use of the DCD donor pool. The British Transplantation Society ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated. This manuscript summarises the relevant recommendations from chapters specifically related to organ donation.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100791"},"PeriodicalIF":4.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10031925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}